Novocure™ is a private commercial-stage oncology company dedicated to the advancement of tumor treating fields TTF therapy for patients with solid tumors. TTF therapy is an innovative antimitotic treatment that attempts to slow or reverse tumor progression by inducing tumor cell death.
Our company pioneered the concept that the electric properties of cells can be used as an effective target for an anti-neoplastic therapy. Founded by Professor Yoram Palti in 2000, Novocure has grown to become a global organization with employees in six countries. We have been fortunate throughout our expansion to attract a world class team with a shared passion to provide cancer patients with a new treatment option.
Novocure’s US operations are based in Portsmouth, NH. The Global Commercialization Team is located in New York City and the company maintains a research facility in Haifa, Israel.
Balancing science, care and commitment, SCRI is proud to promote partnership with community physicians and academic institutions. We pride ourselves on our unique offering, focused on aligning science, sites and services. By encouraging breakthrough partnerships, we are pushing innovation forward, closing the gap on cancer, and providing a better future for all. SCRI participates in both industry-sponsored and investigator-initiated clinical trials and conducts phase 1 through phase 3 and outcomes-based clinical trials. Our academic partnerships with Yale Cancer Center, Peggy and Charles Stephenson Cancer Center at The Oklahoma University and University College London further enable us to provide academic and collaborative leadership. Our oncology drug development program accrues more than 700 patients each year and our facilities include full pharmacokinetic and pharmacodynamics capabilities for our four drug development program sites: SCRI Drug Development Unit (Nashville, TN), Florida Cancer Specialists (Fort Myers, FL), Peggy and Charles Stephenson Cancer Center at Oklahoma University (Oklahoma City, OK) and Sarah Cannon Research UK (London, UK). SCRI uses a network model, with more than 700 community-based oncologists across 25 states and the United Kingdom, making our trials easily accessible to a broad patient base. SCRI has seven strategic oncology sites with over 200 investigators who see 75,000 new patients each year.